Entrada Therapeutics, Inc.

Contributing Author

Recent Articles by Entrada Therapeutics, Inc.

Oct-21	Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer TRDA -6.81% GlobeNewswire
Oct-14	Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study TRDA -6.38% GlobeNewswire
Oct-14	Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 TRDA -6.38% GlobeNewswire
Sep-10	Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program TRDA -9.70% GlobeNewswire
Sep-02	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Aug-05	Entrada Therapeutics Reports Second Quarter 2026 Financial Results TRDA GlobeNewswire
Jun-02	Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study TRDA GlobeNewswire
Jun-01	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
May-07	Entrada Therapeutics Reports First Quarter 2026 Financial Results TRDA -57.27% GlobeNewswire
May-07	Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study TRDA -57.27% GlobeNewswire
May-06	Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 TRDA GlobeNewswire
Mar-02	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Feb-26	Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results TRDA +6.76% GlobeNewswire
Feb-17	Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study TRDA GlobeNewswire
Feb-04	Entrada Therapeutics to Present at Upcoming Investor Conferences TRDA -8.23% GlobeNewswire
Jan-08	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases TRDA GlobeNewswire
Dec-17	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference TRDA GlobeNewswire
Dec-04	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Nov-06	Entrada Therapeutics Reports Third Quarter 2025 Financial Results TRDA GlobeNewswire
Oct-28	Entrada Therapeutics to Present at Upcoming Investor Conferences TRDA GlobeNewswire
Sep-05	Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program TRDA GlobeNewswire
Sep-02	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
Aug-06	Entrada Therapeutics Reports Second Quarter 2025 Financial Results TRDA GlobeNewswire
Jun-03	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors TRDA GlobeNewswire
Jun-02	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA +7.11% GlobeNewswire
May-28	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping TRDA GlobeNewswire
May-08	Entrada Therapeutics Reports First Quarter 2025 Financial Results TRDA +5.64% GlobeNewswire

Entrada Therapeutics, Inc.

Recent Articles by Entrada Therapeutics, Inc.

Upgrade your Finviz experience